Dr. Reddy’s, American Remedies merger through - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr. Reddy’s, American Remedies merger through

Mar 7, 2000

The legal merger between Dr Reddy’s Laboratories (DRL) and American Remedies (ARL) is through. The merger ratio has been fixed at 1:12 i.e. 1 share of DRL for every 12 shares of ARL. DRL is one of the fastest growing companies in the pharmaceutical sector having a 1.4% market share in domestic formulations. The company has grown from being a bulk drug company to a respected formulation based company. It has products such as omeprazole (gastro–intestinal), ciprolet (anti–infective) Nise (pain and fever), Enam (cardiovascular) etc.

ARL’s product range includes Mucolite, Becozinc, Antoxid, GLA, BioE, which account for 60% of the company’s estimated Rs 1 bn sales (FY 2000 estimates). More importantly, ARL has a prescription base of around one lakh doctors which provides DRL with another channel to sell its own products in the domestic market.

DRL acquired a 45% stake in ARL a few months back and has already acquired a further 15–20% stake from the associates of ARL’s promoters. An open offer for to acquire another 20% from the company’s shareholders enabled DRL to take its holding to 84% of the equity of ARL.In a way the legal merger is a formality for DRL since the company has already integrated the manufacturing as well as the marketing network of ARL into its operations.

Market View:
Analysts are convinced of the seriousness of the R & D efforts of the company and have rated the stock as a buy. The company has three new original molecules in its research pipeline. One is an anti–cancer compound, another is a Cox II inhibitor (anti–pain) and third was a compound indicated for metabolic disorders. The company foresees licensing out two of these to MNCs for clinical trials in the near future. Perhaps the only dampener could be the fact that 20% of its earnings from its exports to Russia would come under the tax net.

Equitymaster requests your view! Post a comment on "Dr. Reddy’s, American Remedies merger through". Click here!

  

More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

How to Hit Rs 100 Crore Wealth in Your Lifetime (Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 26, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - MYLAN COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS